The road ahead for the tau hypothesis of Alzheimer’s disease
First tau data — delivered by Genentech — put antibody therapies on shaky ground
First tau data — delivered by Genentech — put antibody therapies on shaky ground.
The Phase II miss of the first tau antibody to reach that stage continue the tradition in Alzheimer’s disease of bad news with hard-to-interpret ramifications for the target. At a minimum, the data call into question the use of antibodies in attacking a target that primarily resides inside cells.
At least nine anti-tau therapies have begun clinical testing, and the protein has gained status as the next big target, and maybe hope, behind amyloid (see “Is Tau the New Amyloid?”).
Six of those therapies are antibodies.
Semorinemab from AC Immune S.A.